Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

NCT05759572 PHASE2 RECRUITING

This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.

Details

Lead sponsor	Fudan University
Phase	PHASE2
Status	RECRUITING
Enrolment	145
Start date	Wed Feb 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Breast Cancer Metastatic

Interventions

• Apatinib
• Dalpiciclib
• Fulvestrant/AI

Countries

China